VKTX vs HIMS Stock Comparison: AI Score, Valuation, Performance and Upside
VKTX and HIMS both attract investors interested in weight-loss treatment but they are entirely different businesses. Viking is developing a drug and has no revenue, so its value depends on clinical trial outcomes. Hims & Hers is a consumer subscription platform that already generates revenue by distributing treatments, including weight management, and its risks are regulatory and marketing-driven rather than clinical.
Use this VKTX vs HIMS comparison to distinguish owning the molecule from owning the customer relationship. Viking's upside comes from intellectual property that, if approved, would be very valuable. Hims & Hers captures margin on distribution and retention but is vulnerable to rule changes and to decisions made by the companies that actually own the drugs.
VKTX holds the edge across 4 of 5 key metrics in this comparison. VKTX has delivered stronger 1-year price return (+33.53% vs -46.38%), though HIMS has the better forward P/E setup (29.03x vs -7.76x for VKTX). Analyst consensus implies meaningfully more upside for VKTX (+175.81%) than for HIMS (+7.36%).
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- Want direct exposure to a next-generation obesity drug candidate
- Accept that the outcome hinges on pivotal trial data rather than execution
- Understand there is no revenue to cushion a clinical setback
- Are treating it as a speculative position
- Prefer a revenue-generating consumer subscription business to a clinical bet
- Believe telehealth will keep taking share of routine prescription categories
- Value diversification across sexual health, dermatology, mental health, and weight loss
- Accept regulatory and customer acquisition cost risk as the main threats
| Metric | VKTX | HIMS |
|---|---|---|
| AI scorei | 46.0 | 42.5 |
| AI ranki | #670 | #844 |
| Latest closei | $35.56 | $29.42 |
| 1M returni | +3.43% | -1.37% |
| 6M returni | +9.35% | +51.81% |
| 1Y returni | +33.53% | -46.38% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | VKTX | HIMS |
|---|---|---|
| 1Y ago | $14.17K (+41.7%) started 2025-09-25 | $5.36K (-46.4%) started 2025-09-25 |
| 5Y ago | $53.31K (+433.1%) started 2021-09-27 | $35.19K (+251.9%) started 2021-09-27 |
| 10Y ago | $269.39K (+2593.9%) started 2016-09-26 | $30.02K (+200.2%) started 2019-09-13 |
Hypothetical — past performance does not guarantee future results.
| Metric | VKTX | HIMS |
|---|---|---|
| Market capi | $3.91B | $6.79B |
| Trailing P/Ei | N/A | N/A |
| Forward P/Ei | -7.76 | 29.03 |
| Price/Salesi | N/A | N/A |
| EV/Revenuei | N/A | 2.85 |
| Analyst targeti | $92.39 | $31.23 |
| Target upsidei | +175.81% | +7.36% |
| Metric | VKTX | HIMS |
|---|---|---|
| Revenue growthi | N/A | 38.20% |
| Earnings growthi | N/A | N/A |
| EPS growthi | N/A | N/A |
| FCF margini | N/A | +32.95% |
| Operating margini | 0.00% | -12.75% |
| Profit margini | 0.00% | -5.51% |
| ROIC proxyi | -88.85% | -32.03% |
| Return on equityi | -88.85% | -32.03% |
| Dividend yieldi | N/A | N/A |
| Payout ratioi | 0.00% | 0.00% |
| Dividend growth streaki | N/A | N/A |
| Betai | 0.69 | 2.42 |
| Debt/equityi | 1.00 | 477.13 |
| Current ratioi | 4.72 | 0.93 |
| Quick ratioi | 4.58 | 0.82 |
Over the past year, VKTX and HIMS have moved weakly in the same direction (correlation of 0.20), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | VKTX | HIMS |
|---|---|---|---|
| 1Y | Growthi | +41.73% | -46.38% |
| CAGRi | +41.80% | -46.41% | |
| Volatilityi | 68.59% | 91.78% | |
| Sharpe ratioi | 0.77 | -0.29 | |
| Sortino ratioi | 1.35 | -0.45 | |
| Max drawdowni | 35.53% | 76.86% | |
| Current drawdowni | 15.59% | 53.12% | |
| Avg drawdowni | 16.19% | 49.38% | |
| Ulcer Indexi | 18.37% | 52.09% | |
| Max daily dropi | 11.76% | 16.03% | |
| Max wkly dropi | 13.56% | 32.71% | |
| 5Y | Growthi | +433.13% | +251.91% |
| CAGRi | +39.81% | +28.65% | |
| Volatilityi | 103.21% | 84.29% | |
| Sharpe ratioi | 0.71 | 0.66 | |
| Sortino ratioi | 1.44 | 1.03 | |
| Max drawdowni | 78.86% | 78.88% | |
| Current drawdowni | 62.37% | 57.20% | |
| Avg drawdowni | 44.97% | 32.28% | |
| Ulcer Indexi | 50.25% | 37.46% | |
| Max daily dropi | 42.12% | 34.63% | |
| Max wkly dropi | 38.89% | 39.06% | |
| 10Y | Growthi | +2593.94% | +200.20% |
| CAGRi | +39.03% | +16.92% | |
| Volatilityi | 97.81% | 77.57% | |
| Sharpe ratioi | 0.70 | 0.53 | |
| Sortino ratioi | 1.43 | 0.82 | |
| Max drawdowni | 89.26% | 87.29% | |
| Current drawdowni | 62.37% | 57.20% | |
| Avg drawdowni | 50.82% | 43.70% | |
| Ulcer Indexi | 56.24% | 52.14% | |
| Max daily dropi | 42.12% | 34.63% | |
| Max wkly dropi | 38.89% | 39.06% |
| Category | VKTX | HIMS |
|---|---|---|
| Company | Viking Therapeutics, Inc. | Hims & Hers Health, Inc. |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Drug Manufacturers - Specialty & Generic |
| Core business | Clinical-stage biotechnology company developing metabolic treatments, led by a dual GIP and GLP-1 receptor agonist in injectable and oral forms, plus liver disease programmes. No approved products. | Direct-to-consumer telehealth platform selling subscription treatments across sexual health, hair loss, dermatology, mental health, and weight management, combining online clinical consultations with fulfilment of prescribed and over-the-counter products. |
| Investor focus | Pivotal trial results, tolerability and discontinuation data, oral formulation progress, cash runway, and partnership prospects. | Subscriber growth and retention, weight-loss offering composition after compounding restrictions tightened, customer acquisition cost, and gross margin by category. |
- Owns intellectual property in a category with very large potential commercial value
- Earlier data placed it among the more closely followed obesity challengers
- Positive pivotal results would be transformational relative to its size
- Subscription model produces recurring revenue and improving unit economics as the base grows
- Strong consumer brand and marketing capability in categories patients prefer to handle privately
- Already generating revenue and has reached profitability, unlike most healthcare growth stories
- No revenue, so the investment is a pure clinical outcome bet
- Requires a partner or very large capital raise to commercialise
- Competes against two entrenched companies with enormous manufacturing advantages
- Regulatory changes around compounded GLP-1 medications have already forced the weight-loss offering to be reworked
- Heavy dependence on paid marketing, so customer acquisition cost inflation directly compresses margins
- Does not own the underlying drugs, leaving it exposed to supply and pricing decisions by manufacturers
Compare more than two at a time
This page is a fixed writeup on VKTX and HIMS. Our comparison engine is the interactive version: load up to five tickers, switch timeframes, and get the correlation, drawdown, and overlap analysis that a static page can't show.
Add three more names beside VKTX and HIMS, mixing stocks and ETFs in the same table — useful when the real question is which of a whole peer group to own.
AI score, forward P/E, analyst target upside, operating margin, and revenue growth are scored head-to-head, with a running tally of which ticker leads on how many metrics.
Volatility, Sharpe and Sortino ratios, maximum, current, and average drawdown, Ulcer Index, and worst single-day and single-week drops across every timeframe.
Pairwise daily-return correlation for every combination, so you can see whether two holdings actually diversify each other or just move together.
A scatter plot of forward P/E against return on equity, plus drawdown and 30-day rolling volatility charts, to separate what is cheap from what is merely beaten down.
For ETFs, a top-holdings comparison that exposes hidden overlap between funds. Every comparison exports to CSV for your own spreadsheet work.
Two comparisons a week are free without an account. A 14-day trial removes the limit and adds AI price forecasts, stock rankings, saved watchlists, and the intrinsic value calculator — no credit card required.
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Full valuation workup with AI Score, Monte Carlo forecast, and bull/bear case — free preview, premium data from $3.99.